Loading...
XNYSCRL
Market cap9.70bUSD
Jan 07, Last price  
189.76USD
1D
0.12%
1Q
1.10%
Jan 2017
149.06%
Name

Charles River Laboratories International Inc

Chart & Performance

D1W1MN
XNYS:CRL chart
P/E
20.44
P/S
2.35
EPS
9.28
Div Yield, %
0.00%
Shrs. gr., 5y
0.97%
Rev. gr., 5y
12.75%
Revenues
4.13b
+3.86%
766,917,0001,122,228,0001,058,385,0001,230,626,0001,343,493,0001,202,551,0001,133,416,0001,142,647,0001,129,530,0001,165,528,0001,297,662,0001,363,302,0001,681,432,0001,857,601,0002,266,096,0002,621,226,0002,923,933,0003,540,160,0003,976,060,0004,129,409,000
Net income
475m
-2.39%
89,792,000141,999,000-55,783,000154,406,000-521,843,000114,441,000-336,669,000109,566,00097,295,000102,828,000126,698,000149,313,000154,765,000123,355,000226,373,000252,019,000364,304,000390,982,000486,226,000474,624,000
CFO
684m
+10.37%
184,827,000236,702,000164,370,000284,248,000279,949,000225,044,000169,013,000205,283,000207,900,000207,139,000251,051,000286,358,000298,319,000316,265,000441,140,000480,936,000546,575,000760,799,000619,640,000683,898,000
Earnings
Feb 12, 2025

Profile

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
IPO date
Jun 23, 2000
Employees
20,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,129,409
3.86%
3,976,060
12.31%
Cost of revenue
2,626,853
2,513,409
Unusual Expense (Income)
NOPBT
1,502,556
1,462,651
NOPBT Margin
36.39%
36.79%
Operating Taxes
100,914
130,379
Tax Rate
6.72%
8.91%
NOPAT
1,401,642
1,332,272
Net income
474,624
-2.39%
486,226
24.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
(24,155)
(13,541)
BB yield
0.20%
0.12%
Debt
Debt current
50,203
Long-term debt
3,904,849
3,487,021
Deferred revenue
(388,315)
25,795
Other long-term liabilities
(196,043)
149,027
Net debt
3,384,267
2,991,710
Cash flow
Cash from operating activities
683,898
619,640
CAPEX
(318,528)
(324,733)
Cash from investing activities
(563,155)
(607,922)
Cash from financing activities
(85,521)
(42,397)
FCF
984,077
984,467
Balance
Cash
276,771
233,912
Long term investments
243,811
311,602
Excess cash
314,112
346,711
Stockholders' equity
1,753,420
1,218,565
Invested Capital
6,634,458
5,959,195
ROIC
22.26%
23.33%
ROCE
21.04%
22.43%
EV
Common stock shares outstanding
51,451
51,301
Price
236.40
8.49%
217.90
-40.98%
Market cap
12,163,016
8.81%
11,178,488
-41.12%
EV
15,609,399
14,217,410
EBITDA
1,816,680
1,766,521
EV/EBITDA
8.59
8.05
Interest
136,710
59,291
Interest/NOPBT
9.10%
4.05%